Loading...
The approval of sotorasib earlier this year was felt to be a watershed moment in cancer therapeutics, primarily because KRAS was considered an “undruggable” target for many years. RAS proteins are a family of prototypical oncogenes that are mutated in many human cancers. KRAS is the most frequently mutated isoform of RAS mutations (86%), and is mutated in 90% of pancreatic, 40% of colorectal, and 30% of lung cancers. Mutant KRAS has long been referred to as an undruggable target because of its unusual shape. Compared with other proteins, its relatively smooth protein structure meant that designing inhibitors to bind to surface grooves was difficult, stalling progress in drug development for many years. The FDA's accelerated approval of the …